期刊文献+

螺内酯对冠心病患者内皮细胞功能的影响

Effect of antisterone on endothelial cell function in coronary heart disease
下载PDF
导出
摘要 目的 本实验旨在探讨螺内酯对冠心病患者内皮细胞功能的影响。方法 选择 5 0例冠心病患者作为实验组 ,5 0例健康者作为对照组 ,给药前先测定实验组和对照组的内皮素 (ET)、血栓素 A2 (TXA2 )、一氧化氮 (NO)、前列环素 (PGI2 ) ,再予以实验组螺内酯 2 0 m g/ d,3个月后再测定实验组的 ET、TXA2 、NO、PGI2 并进行比较。结果 给药前实验组的 ET、TXA2 水平较对照组高 ,NO、PGI2 水平较对照组低 ;给药后 NO、PGI2 水平较给药前高 ,ET、TXA2 较给药前低。结论 螺内酯可以有效地改善血管内皮细胞功能 ,对逆转冠心病患者内皮细胞功能紊乱起着重要的作用。 Objective To investigate the effect of antisterone on the function of endothelial cell. Methods 50 coronary heart disease patients were selected in experiment group and 50 healthy people as a control group. ET,TXA 2,NO,PGI 2 levels were tested in both groups, then antisterone 20mg were taken once a day, and all the indexes after 3 months were tested. Results Before taking antisterone, ET and TXA 2 levels of experiment group were higher than that of control group, NO and PGI 2 levels in experiment group were lower than that of control group. After taking antisterone, NO and PGI 2 levels were increased and ET and TXA 2 levels were decreased. Conclusion Antisterone can effectively improve the function of blood vessel endothelial cell, and plays important role in reversing the dysfunction of endothelial cell in coronary heart disease.
出处 《中国心血管杂志》 2004年第6期403-405,共3页 Chinese Journal of Cardiovascular Medicine
关键词 冠心病 螺内酯 内皮细胞功能 Coronary heart disease Antisterone Function of endothelial cell.
  • 相关文献

参考文献16

  • 1Pitt B, Zannad F,Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation study Investigators [J]. N Engl J Med,1999, 341:709-717.
  • 2Farguharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin Ⅱ conversion in patients with chronic heart failure[J]. Circulation, 2000,101:594-597.
  • 3Mehta JL. Endothelium, coronary vasodilation, and organic nitrates[J]. Am Heart J, 1995, 129:382-391.
  • 4Anderson TJ, Gerhard MD, Meredith IT, et al. Systemic nature of endothelial dysfunction in atherosclerosis [J]. Am J Cardiol, 1995, 75:71B-74B.
  • 5McKenzie DB, Cowley AJ. Drug therapy in chronic heart failure[J]. Postgrad Med J, 2003,79:634-642.
  • 6Rochetaing A, Chapon C, Marescaux L, et al. Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats[J]. Can J Physiol Pharmacol, 2003,81:864-872.
  • 7Mill JG, Milanez Mda C, de Resende MM, et al. Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats E J3. Clin Exp Pharmacol Physiol, 2003,30: 739-744.
  • 8Galin I. Barann DA. Congestive heart failure., guidelines for the primary care physician[J]. Mt Sinai J Med, 2003,70:251-264.
  • 9Tilson L, McGowan B, Ryan M, et al. Cost-effectiveness of spironolactone in patients with severe heart failure[J]. Ir J Med Sci, 2003,172:70-72.
  • 10Glick HA, Orzol SM, Tooley JF, et al. Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure[J]. Cardiovasc Drugs Ther, 2002, 16:53-59.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部